C4 Therapeutics (CCCC) Non Operating Investment Income (2020 - 2025)
C4 Therapeutics (CCCC) recorded quarterly Non Operating Investment Income of -$73000.0 in Q2 2025, down 630.0% quarter-over-quarter from -$10000.0 in Q1 2025, and down 21.67% on a YoY basis from -$93191.5 in Q2 2024.
C4 Therapeutics (CCCC) Non Operating Investment Income (2020 - 2025) Analysis & Trends
C4 Therapeutics' Non Operating Investment Income history runs 6 years deep, the most recent figure standing at -$73000.0 for Q2 2025.
- In Q2 2025, Non Operating Investment Income fell 21.67% year-over-year to -$73000.0; the TTM figure through Jun 2025 stood at $410000.0 (down 69.27% YoY), while the FY2025 annual figure was -$3000.0, down 101.67% from the prior year.
- Non Operating Investment Income was -$73000.0 for Q2 2025 at C4 Therapeutics, down from -$10000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $1.7 million in Q1 2023 to a low of -$2.9 million in Q1 2022.
- Historically, Non Operating Investment Income has averaged -$2388.9 across 5 years, with a median of -$66500.0 in 2024.
- Biggest YoY gain for Non Operating Investment Income was 1350.0% in 2021; the steepest drop was 12500.0% in 2021.
- A 5-year view of Non Operating Investment Income shows it stood at -$620000.0 in 2021, then surged by 305.16% to $1.3 million in 2022, then tumbled by 38.92% to $777000.0 in 2023, then slumped by 151.74% to -$402000.0 in 2024, then soared by 81.84% to -$73000.0 in 2025.
- The last three Non Operating Investment Income figures came in at -$73000.0 (Q2 2025), -$10000.0 (Q1 2025), and -$402000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 230,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | C4 Therapeutics | 520.69 Mn | 285.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -73,000.00 |
| Jun 30, 2025 | -73,000.00 |
| Mar 31, 2025 | -10,000.00 |
| Mar 31, 2025 | -10,000.00 |
| Dec 31, 2024 | -402,000.00 |
| Dec 31, 2024 | -402,000.00 |
| Sep 30, 2024 | 895,000.00 |
| Sep 30, 2024 | 895,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | -253,000.00 |
| Mar 31, 2024 | -253,000.00 |
| Dec 31, 2023 | 777,000.00 |
| Dec 31, 2023 | 777,000.00 |
| Sep 30, 2023 | 870,000.00 |
| Sep 30, 2023 | 870,000.00 |
| Jun 30, 2023 | 696,000.00 |
| Jun 30, 2023 | 696,000.00 |
| Mar 31, 2023 | 1.67 Mn |
| Mar 31, 2023 | 1.67 Mn |